Multiple system atrophy of the cerebellar type: Clinical state of the art

Movement Disorders

Volumn 29, Issue 3, 2014, Pages 294-304

  Lin, David J ^a   Hermann, Katherine L ^a   Schmahmann, Jeremy D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Ataxia; Cerebellum; Idiopathic late onset cerebellar ataxia; Multiple system atrophy; Sporadic adult onset ataxia of unknown etiology

Indexed keywords

ALPHA SYNUCLEIN; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BROMOCRIPTINE; DEXTROMETHORPHAN PLUS QUINIDINE; FLUDROCORTISONE; FLUORODEOXYGLUCOSE; GLYCOPYRRONIUM BROMIDE; LEVODOPA; LISURIDE; MIDODRINE; NEUROTRANSMITTER; OXYBUTYNIN; PERGOLIDE; PRIMIDONE; PYRIDOSTIGMINE; SCOPOLAMINE; THREO 3,4 DIHYDROXYPHENYLSERINE; TOLTERODINE; TRIHEXYPHENIDYL;

AKINESIA; AUTONOMIC DYSFUNCTION; BEHAVIOR DISORDER; BLADDER DYSFUNCTION; BRAIN CORTEX; BRAIN STEM; CELL INCLUSION; CELL NUCLEUS MEMBRANE; CEREBELLAR ATAXIA; CEREBELLUM; CEREBELLUM DEGENERATION; CEREBROSPINAL FLUID; CLINICAL CLASSIFICATION; CLINICAL FEATURE; COGNITIVE DEFECT; COMPRESSION STOCKING; CONSTIPATION; CRYING; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DYSAUTONOMIA; DYSPHAGIA; DYSTONIA; ELECTROMYOGRAPHY; ERECTILE DYSFUNCTION; FALL RISK; FLUID INTAKE; FRACTIONAL ANISOTROPY; FRIEDREICH ATAXIA; GLUCOSE METABOLISM; HUMAN; HYPOTHYROIDISM; IDIOPATHIC DISEASE; IDIOPATHIC LATE ONSET CEREBELLAR ATAXIA; INDWELLING CATHETER; LIGHT CHAIN; MIDDLE CEREBELLAR PEDUNCLE; MUSCLE RIGIDITY; NERVE DEGENERATION; NEUROFILAMENT; NEUROIMAGING; NONHUMAN; NORADRENERGIC SYSTEM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OCCUPATIONAL THERAPY; ONSET AGE; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PATHOLOGICAL LAUGHTER; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN CEREBROSPINAL FLUID LEVEL; PUTAMEN; QUALITY OF LIFE; REINNERVATION; REM SLEEP; REVIEW; SALIVATION; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; SLEEP DISORDER; SPINOCEREBELLAR DEGENERATION; STRESS INCONTINENCE; STRIATONIGRAL DEGENERATION; STRIDOR; SUPERIOR CEREBELLAR PEDUNCLE; SWALLOWING; TENSION HEADACHE; THALAMUS; TREMOR; URETHRITIS; URINARY DYSFUNCTION; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; URINE RETENTION; UTERUS PROLAPSE; WHITE MATTER; WOLFRAM SYNDROME; ANIMAL; DISEASE MODEL; METABOLISM; MULTIPLE SYSTEM ATROPHY; PARKINSONIAN DISORDERS;

ALPHA-SYNUCLEIN; ANIMALS; CEREBELLAR ATAXIA; CEREBELLUM; DISEASE MODELS, ANIMAL; HUMANS; MULTIPLE SYSTEM ATROPHY; PARKINSONIAN DISORDERS;

EID: 84896139916     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25847     Document Type: Review

References (139)

1. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670-676.
2. Quinn N. Multipe system atrophy-the nature of the beast. J Neurol Neurosurg Psychiatry 1989;Suppl:78-89.
3. Wenning GK, Stefanova N. Recent developments in multiple system atrophy. J Neurol 2009;256:1791-1808.
4. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997;49:1284-1288.
5. Schrag A, Ben Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999;354:1771-1775.
6. Tison F, Yekhlef F, Chrysostome V, Sourgen C. Prevalence of multiple system atrophy. Lancet 2000;355:495-496.
7. Saito Y, Matsuoka Y, Takahashi A, Ohno Y. Survival of patients with multiple system atrophy. Intern Med 1994;33:321-325.
8. Schrag A, Wenning GK, Quinn N, Ben-Shlomo Y. Survival in multiple system atrophy. Mov Disord 2008;23:294-296.
9. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989;94(1-3):79-100.
10. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 1998;249(2-3):180-182.
11. Tu PH, Galvin JE, Baba M, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 1998;44:415-422.
12. Spillantini MG, Crowther RA, Jakes R, et al. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 1998;251:205-208.
13. Geser F, Seppi K, Stampfer-Kountchev M, et al. The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm 2005;112:1677-1686.
14. May S, Gilman S, Sowell BB, et al. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord 2007;22:2371-2377.
15. Gilman S, May SJ, Shults CW, et al. The North American Multiple System Atrophy Study Group. J Neural Transm 2005;112:1687-1694.
16. Dickson DW. Parkinson's disease and parkinsonism: neuropathology [serial online]. Cold Spring Harb Perspect Med 2012;2;a009258.
17. Dejerine J, Thomas A. L'atrophie olivo-ponto-cerebelleuse. Nouv Icon Salpetriere 1900;13:330-370.
18. Bradbury S, Eggleston C. Postural hypotension. Am Heart J 1925;1:73-86.
19. Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study. Arch Neurol 1960;2:511-527.
20. Adams R, van Bogaert L, van der Eecken H. Dégénérescences nigro-striées et cerebello-nigro-striées. Psychiat Neurol 1961;142:219-232.
21. Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 1969;32:28-34.
22. Fernagut P-O, Tison F. Animal models of multiple system atrophy. Neuroscience 2012;211:77-82.
23. Arima K, Ueda K, Sunohara N, et al. NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol 1998;96:439-444.
24. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492-501.
25. Goedert M. Parkinson's disease and other alpha-synucleinopathies. Clin Chem Lab Med 2001;39:308-312.
26. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94-98.
27. Hanna PA, Jankovic J, Kirkpatrick JB. Multiple system atrophy: the putative causative role of environmental toxins. Arch Neurol 1999;56:90-94.
28. Hara K, Momose Y, Tokiguchi S, et al. Multiplex families with multiple system atrophy. Arch Neurol 2007;64:545-551.
29. Wullner U, Schmitt I, Kammal M, et al. Definite multiple system atrophy in a German family. J Neurol Neurosurg Psychiatry 2009;80:449-450.
30. Hohler AD, Singh VJ. Probable hereditary multiple system atrophy-autonomic (MSA-A) in a family in the United States. J Clin Neurosci 2012;19:479-480.
31. The Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med 2013;369:233-244.
32. Klockgether T. Sporadic ataxia with adult onset: classification and diagnostic criteria. Lancet Neurol 2010;9:94-104.
33. Manto M, Schmahmann JD, Rossi F, Gruol DL, Koibuchi N, eds. Handbook of the Cerebellum and Cerebellar Disorders. New York: Springer; 2012.
34. Grant R, Graus F. Paraneoplastic movement disorders. Mov Disord 2009;24:1715-1724.
35. Honnorat J, Saiz A, Giometto B, et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 2001;58:225-230.
36. Hadjivassiliou M, Grunewald RA, Chattopadhyay AK, et al. Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia. Lancet 1998;352:1582-1585.
37. Abele M, Schols L, Schwartz S, Klockgether T. Prevalence of antigliadin antibodies in ataxia patients. Neurology 2003;60:1674-1675.
38. Bushara KO, Goebel SU, Shill H, et al. Gluten sensitivity in sporadic and hereditary cerebellar ataxia. Ann Neurol 2001;49:540-543.
39. McCarthy CL, McColgan P, Martin P. Acute cerebellar ataxia due to Epstein-Barr virus. Pract Neurol 2012;12:238-240.
40. Cho TA, Schmahmann JD, Cunnane ME. Case records of the Massachusetts General Hospital. Case 30-2013. A 19-year-old man with otalgia, slurred speech, and ataxia. N Engl J Med 2013;369:1253-1261.
41. Matsunaga A, Ikawa M, Fujii A, et al. Hashimoto's encephalopathy as a treatable adult-onset cerebellar ataxia mimicking spinocerebellar degeneration. Psychiatr Neurol 2013;69:14-20.
42. Hariri OR, Khachekian A, Muilli D, et al. Acute-onset cerebellar symptoms in Lhermitte-Duclos disease: case report. Cerebellum 2013;12:127-130.
43. Mousali YM, Obeid T, Alshamy AM, Abdullah LS. Cerebellar syndromes as a late presentation of Langerhans cell histiocytosis. Neurosciences (Riyadh) 2004;9:309-311.
44. Fearnley JM, Stevens JM, Rudge P. Superficial siderosis of the central nervous system. Brain 1995;118 (pt 4):1051-1066.
45. van Harskamp NJ, Rudge P, Cipolotti L. Cognitive and social impairments in patients with superficial siderosis. Brain 2005;128(pt 5):1082-1092.
46. Seidel K, Siswanto S, Brunt ERP, et al. Brain pathology of spinocerebellar ataxias. Acta Neuropathol 2012;124:1-21.
47. Pedroso JL, França MC, Braga-Neto P, et al. Nonmotor and extracerebellar features in Machado-Joseph disease: a review. Mov Disord 2013;28:1200-1208.
48. Magana JJ, Velazquez-Perez L, Cisneros B. Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives. Mol Neurobiol 2013;47:90-104.
49. Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001;57:127-130.
50. Berry-Kravis E, Lewin F, Wuu J, et al. Tremor and ataxia in fragile X premutation carriers: blinded videotape study. Ann Neurol 2003;53:616-623.
51. Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003;72:869-878.
52. Kamm C, Healy DG, Quinn NP, et al. The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. Brain 2005;128(pt 8):1855-1860.
53. Koeppen AH. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci 2011;303(1-2):1-12.
54. Berciano J, Boesch S, Perez-Ramos JM, Wenning GK. Olivopontocerebellar atrophy: toward a better nosological definition. Mov Disord 2006;21:1607-1613.
55. Dupre N, Gros-Louis F, Chrestian N, et al. Clinical and genetic study of autosomal recessive cerebellar ataxia type 1. Ann Neurol 2007;62:93-98.
56. Anheim M, Monga B, Fleury M, et al. Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. Brain 2009;132(pt 10):2688-2698.
57. Margolin DH, Kousi M, Chan Y-M, et al. Ataxia, dementia, and hypogonadotropism caused by disordered ubiquitination. N Engl J Med 2013;368:1992-2003.
58. Pierce SB, Walsh T, Chisholm KM, et al. Mutations in the DBP-deficiency protein HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault syndrome. Am J Hum Genet 2010;87:282-288.
59. Lieber DS, Vafai SB, Horton LC, et al. Atypical case of Wolfram syndrome revealed through targeted exome sequencing in a patient with suspected mitochondrial disease [serial online]. BMC Med Genet 2012;13:3.
60. Harding AE. "Idiopathic" late onset cerebellar ataxia. A clinical and genetic study of 36 cases. J Neurol Sci 1981;5:259-271.
61. Schols L, Szymanski S, Peters S, et al. Genetic background of apparently idiopathic sporadic cerebellar ataxia. Hum Genet 2000;107:132-137.
62. Abele M, Burk K, Schols L, et al. The aetiology of sporadic adult-onset ataxia. Brain 2002;125(pt 5):961-968.
63. Kerber KA, Jen JC, Perlman S, Baloh RW. Late-onset pure cerebellar ataxia: differentiating those with and without identifiable mutations. J Neurol Sci 2005;238(1-2):41-45.
64. Brussino A, Gellera C, Saluto A, et al. FMR1 gene premutation is a frequent genetic cause of late-onset sporadic cerebellar ataxia. Neurology 2005;64:145-147.
65. Wardle M, Majounie E, Muzaimi MB, et al. The genetic aetiology of late-onset chronic progressive cerebellar ataxia. A population-based study. J Neurol 2009;256:343-348.
66. Klockgether T, Schroth G, Diener HC, Dichgans J. Idiopathic cerebellar ataxia of late onset: natural history and MRI morphology. J Neurol Neurosurg Psychiatry 1990;53:297-305.
67. Wullner U, Klockgether T, Petersen D, et al. Magnetic resonance imaging in hereditary and idiopathic ataxia. Neurology 1993;43:318-325.
68. Muzaimi MB, Thomas J, Palmer-Smith S, et al. Population based study of late onset cerebellar ataxia in south east Wales. J Neurol Neurosurg Psychiatry 2004;75:1129-1134.
69. Ota S, Tsuchiya K, Anno M, et al. Distribution of cerebello-olivary degeneration in idiopathic late cortical cerebellar atrophy: clinicopathological study of four autopsy cases. Neuropathology 2008;28:43-50.
70. Klockgether T, Burk K, Wullner U, et al. Risk factors for idiopathic cerebellar ataxia of late onset. J Neurol Sci 1998;160:171-174.
71. Abele M, Minnerop M, Urbach H, et al. Sporadic adult onset ataxia of unknown etiology. J Neurol 2007;254:1384-1389.
72. Berciano J. Olivopontocerebellar atrophy. A review of 117 cases. J Neurol Sci 1982;53:253-272.
73. Burk K, Globas C, Wahl T, et al. MRI-based volumetric differentiation of sporadic cerebellar ataxia. Brain 2004;127(pt 1):175-181.
74. Gilman S, Little R, Johanns J, et al. Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy. Neurology 2000;55:527-532.
75. Wenning GK, Kraft E, Beck RW, et al. Cerebellar presentation of multiple system atrophy. Mov Disord 1997;12:115-117.
76. Yamamoto T, Sakakibara R, Uchiyama T, et al. When is Onuf's nucleus involved in multiple system atrophy? A sphincter electromyography study. J Neurol Neurosurg Psychiatry 2005;76:1645-1648.
77. Giladi N, Simon ES, Korczyn AD, et al. Anal sphincter EMG does not distinguish between multiple system atrophy and Parkinson's disease. Muscle Nerve 2000;23:731-734.
78. Vodusek DB. Sphincter EMG and differential diagnosis of multiple system atrophy. Mov Disord 2001;16:600-607.
79. Musegante AFA, Almeida PNS, Barboza AL, Barroso U. Urinary symptoms and urodynamic findings in patients with Machado-Joseph disease. J Neurol 2011;258:623-626.
80. Sakakibara R, Uchiyama T, Arai K, et al. Lower urinary tract dysfunction in Machado-Joseph disease: a study of 11 clinical-urodynamic observations. J Neurol Sci 2004;218(1-2):67-72.
81. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Sphincter EMG as a diagnostic tool in autonomic disorders. Clin Auton Res 2009;19:20-31.
82. Burk K, Buhring U, Schulz JB, et al. Clinical and magnetic resonance imaging characteristics of sporadic cerebellar ataxia. Arch Neurol 2005;62:981-985.
83. Colosimo C. Nonmotor presentations of multiple system atrophy. Nat Rev Neurol 2011;7:295-298.
84. Jecmenica-Lukic M, Poewe W, Tolosa E, Wenning GK. Premotor signs and symptoms of multiple system atrophy. Lancet Neurol 2012;11:361-368.
85. Mascalchi M, Vella A. Magnetic resonance and nuclear medicine imaging in ataxias. Handb Clin Neurol 2012;103:85-110.
86. Brooks DJ, Seppi K; Neuroimaging Working Group on MSA. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 2009;24:949-964.
87. Konagaya M, Konagaya Y, Iida M. Clinical and magnetic resonance imaging study of extrapyramidal symptoms in multiple system atrophy. J Neurol Neurosurg Psychiatry 1994;57:1528-1531.
88. Naka H, Ohshita T, Murata Y, et al. Characteristic MRI findings in multiple system atrophy: comparison of the three subtypes. Neuroradiology 2002;44:204-209.
89. Schrag A, Kingsley D, Phatouros C, et al. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol, Neurosurg Psychiatry 1998;65:65-71.
90. Schrag A, Good CD, Miszkiel K, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000;54:697-702.
91. Kasahara S, Miki Y, Kanagaki M, et al. "Hot cross bun" sign in multiple system atrophy with predominant cerebellar ataxia: a comparison between proton density-weighted imaging and T2-weighted imaging. Eur J Radiol 2012;81:2848-2852.
92. Lee W-H, Lee C-C, Shyu W-C, et al. Hyperintense putaminal rim sign is not a hallmark of multiple system atrophy at 3T. AJNR Am J Neuroradiol 2005;26:2238-2242.
93. Burk K, Skalej M, Dichgans J. Pontine MRI hyperintensities ("the cross sign") are not pathognomonic for multiple system atrophy (MSA) [letter]. Mov Disord 2001;16:535.
94. Lee Y-C, Liu C-S, Wu H-M, et al. The "hot cross bun" sign in the patients with spinocerebellar ataxia. Eur J Neurol 2009;16:513-516.
95. Horimoto Y, Aiba I, Yasuda T, et al. Longitudinal MRI study of multiple system atrophy-when do the findings appear, and what is the course? J Neurol 2002;249:847-854.
96. Seppi K, Schocke MFH, Wenning GK, Poewe W. How to diagnose MSA early: the role of magnetic resonance imaging. J Neural Transm 2005;112:1625-1634.
97. Gilman S, Koeppe RA, Junck L, et al. Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy. Ann Neurol 1994;36:166-175.
98. Prakash N, Hageman N, Hua X, et al. Patterns of fractional anisotropy changes in white matter of cerebellar peduncles distinguish spinocerebellar ataxia-1 from multiple system atrophy and other ataxia syndromes. Neuroimage 2009;47(suppl 2):T72-T81.
99. Boesch SM, Wolf C, Seppi K, et al. Differentiation of SCA2 from MSA-C using proton magnetic resonance spectroscopic imaging. J Magn Reson Imaging 2007;25:564-569.
100. Lirng J-F, Wang P-S, Chen H-C, et al. Differences between spinocerebellar ataxias and multiple system atrophy-cerebellar type on proton magnetic resonance spectroscopy [serial online]. PLoS One 2012;7:e47925.
101. Oz G, Iltis I, Hutter D, et al. Distinct neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple system atrophy. Cerebellum 2011;10:208-217.
102. Pellecchia MT, Pivonello R, Salvatore E, et al. Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia. Clin Endocrinol 2005;62:428-433.
103. Pellecchia MT, Longo K, Pivonello R, et al. Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation test. Ann Neurol 2006;60:611-615.
104. Gardner RC, Schmahmann JD. Arginine test is not reliable for diagnosing cerebellar multiple system atrophy. Ann Neurol 2010;67:404-408.
105. Abdo WF, van de Warrenburg BPC, Munneke M, et al. CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia. Neurology 2006;67:474-479.
106. Hirohata M, Ono K, Morinaga A, et al. Cerebrospinal fluid from patients with multiple system atrophy promotes in vitro α-synuclein fibril formation. Neurosci Lett 2011;491:48-52.
107. Stefanova N, Bucke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol 2009;8:1172-1178.
108. Ubhi K, Low P, Masliah E. Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci 2011;34:581-590.
109. Colosimo C, Tiple D, Wenning GK. Management of multiple system atrophy: state of the art. J Neural Transm 2005;112:1695-1704.
110. Hughes AJ, Colosimo C, Kleedorfer B, et al. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 1992;55:1009-1013.
111. Wenning GK, Ben Shlomo Y, Magalhaes M, et al. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994;117(pt 4):835-845.
112. Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013;12:264-274.
113. Boesch SM, Wenning GK, Ransmayr G, Poewe W. Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry 2002;72:300-303.
114. Low PAP, Singer WW. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol 2008;7:451-458.
115. Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 1997;277:1046-1051.
116. Lanier JB, Mote MB, Clay EC. Evaluation and management of orthostatic hypotension. Am Fam Physician 2011;84:527-536.
117. Kaufmann H. L-dihydroxyphenylserine (droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res 2008;18(suppl 1):19-24.
118. Mathias CJ, Senard JM, Braune S, Watson L, Araqishi A, Keeling JE, Taylor MD. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res 2001;11:235-242.
119. Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 2003;108:724-728.
120. Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol 1994;151:1336-1341.
121. Wortzel HS, Anderson CA, Arciniegas DB. Treatment of pathologic laughing and crying. Curr Treat Options Neurol 2007;9:371-380.
122. Scherfler C, Puschban Z, Ghorayeb I, et al. Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy). Neuroscience 2000;99:43-54.
123. Ghorayeb I, Puschban Z, Fernagut P-O, et al. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration. Exp Neurol 2001;167:133-147.
124. Waldner R, Puschban Z, Scherfler C, et al. No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy). Neuroscience 2001;102:581-592.
125. Ghorayeb I, Fernagut P-O, Hervier L, et al. A "single toxin-double lesion" rat model of striatonigral degeneration by intrastriatal 1-methyl-4-phenylpyridinium ion injection: a motor behavioural analysis. Neuroscience 2002;115:533-546.
126. Shults CW, Rockenstein E, Crews L, et al. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci 2005;25:10689-10699.
127. Yazawa I, Giasson BI, Sasaki R, et al. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 2005;45:847-859.
128. Kahle PJ, Neumann M, Ozmen L, et al. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 2002;3:583-588.
129. Ubhi K, Rockenstein E, Mante M, et al. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci 2010;30:6236-6246.
130. Stefanova N, Georgievska B, Eriksson H, et al. Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. Neurotox Res 2012;21:393-404.
131. Kollensperger M, Krismer F, Pallua A, et al. Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. Mov Disord 2011;26:507-515.
132. Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol 2008;210:421-427.
133. Valera E, Ubhi K, Mante M, Rockenstein E, Masliah E. Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy. Glia 2014;62:317-337.
134. Stemberger S, Jamnig A, Stefanova N, et al. Mesenchymal stem cells in a transgenic mouse model of multiple system atrophy: immunomodulation and neuroprotection [serial online]. PLoS One 2011;6:e19808.
135. Park H-J, Bang G, Lee BR, et al. Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy parkinsonism. Cell Transplant 2011;20:827-835.
136. Lee PH, Lee JE, Kim H-S, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol 2012;72:32-40.
137. Lee PH, Kim JW, Bang OY, et al. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 2008;83:723-730.
138. Hasegawa T, Baba T, Kobayashi M, et al. Role of TPPP/p25 on α-synuclein-mediated oligodendroglial degeneration and the protective effect of SIRT2 inhibition in a cellular model of multiple system atrophy. Neurochem Int 2010;57:857-866.
139. Auluck PK, Caraveo G, Lindquist S. α-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu Rev Cell Dev Biol 2010;26:211-233.